Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

121. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update

HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update | CADTH.ca Find the information you need HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review (...) of Diagnostic Test Accuracy and Clinical Evidence – An Update Last updated: May 30, 2019 Project Number: RC1124-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the diagnostic test accuracy of self-sampled HPV tests compared with clinician-sampled HPV tests or cytology for asymptomatic cervical cancer screening? What is the clinical evidence regarding the agreement or concordance of self-sampled HPV tests and clinician

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

122. Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines

Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines | CADTH.ca Find the information you need Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Last updated: August 22, 2019 Project Number: RA1060-000 Product Line: Research Type: Devices and Systems (...) Report Type: Reference List Result type: Report Question What is the clinical utility of prostate-specific antigen testing for prostate cancer? What are the evidence-based guidelines on the use of prostate-specific antigen testing for prostate cancer screening? Key Message Two systematic reviews were identified regarding the clinical utility of prostate-specific antigen testing for prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of prostate-specific

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

123. Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines

Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 27, 2019 Project Number: RB1389-000 Product (...) Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of telemammography for the diagnosis of breast cancer? What is the cost-effectiveness of telemammography for the diagnosis of breast cancer? What are the evidence based guidelines regarding the use of telemammography for the diagnosis of breast cancer? Key Message No relevant health technology assessments, systematic reviews, meta-analyses, randomized-controlled

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

124. Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: September 5, 2019 Project Number (...) : RA1061-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of radical prostatectomy for early-stage or screen-detected prostate cancer? What is the clinical effectiveness of radiation therapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of radical prostatectomy for prostate cancer? What are the evidence-based guidelines on the use of radiation therapy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

125. Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness

Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness Cognitive Behavioural Therapy for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness Last updated: September 16, 2019 Project Number: RC1181-000 Product Line: Research (...) Type: Non-Pharma Mental Health Intervention Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of cognitive behavioural therapy for chronic non-cancer pain? Key Message There were five systematic reviews included in this report, four of which were Cochrane reviews. Four of the five included systematic reviews had one weakness in the AMSTAR critical domains. The clinical effectiveness of cognitive behavioural therapy was assessed in several

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

126. Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration (...) Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: June 6, 2019 Project Number: RC1127-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of varying treatment sequences of androgen receptor targeted agents in patients with castrate-resistant prostate cancer? What is the comparative cost-effectiveness of varying treatment sequences of androgen

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

127. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) : Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Last updated: June 11, 2019 Project Number: RB1351-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer diagnosis? What is the diagnostic accuracy of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

128. Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines

Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines Smaller Quantity Opioid Prescribing for Chronic Non-Cancer Pain: Clinical Effectiveness and Guidelines Last updated: June 28, 2019 Project Number (...) : RA1041-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of prescribing opioids in smaller quantities for patients with chronic non-cancer pain? What are the evidence-based guidelines associated with opioid prescribing for patients with chronic non-cancer pain? Key Message One non-randomized study and three evidence-based guidelines were identified regarding short-term prescribing of opioids for patient with chronic non

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

129. Nerlynx for Hormone Receptor-Positive Breast Cancer – Details

Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details | CADTH.ca Find the information you need Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Project Number pCODR 10172 Brand Name Nerlynx Generic Name Neratinib Strength 40 mg Tumour Type Breast Indication Hormone Receptor-Positive Breast Cancer Funding Request For patients with HER2-positive, hormone (...) receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months Review Status Open for Feedback on Recommendation Pre Noc Submission Yes NOC Date July 16, 2019 Manufacturer Knight Therapeutics Inc. Sponsor Knight Therapeutics Inc. Submission Date April 18, 2019 Submission Deemed Complete May 3, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ May 3, 2019 Check-point meeting July 4, 2019 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

130. Tecentriq for Small Cell Lung Cancer – Details

Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details Project Number pCODR 10156 Brand Name Tecentriq Generic Name Atezolizumab Strength 60 mg/mL Tumour Type Lung Indication Small Cell Lung Cancer (SCLC) Funding Request For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC

2019 CADTH - Pan Canadian Oncology Drug Review

131. Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details

Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details | CADTH.ca Find the information you need Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Project Number pCODR 10201 Brand Name Zytiga (Resubmission) Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed high (...) -risk metastatic castration sensitive prostate cancer without small-cell histologic features. Patients required to have at least two of the three following high-risk factors: Gleason score of 8 or more, at least 3 bone lesions, and presence of visceral metastasis. Less than 3 months of androgen deprivation therapy (or orchiectomy) for metastatic disease. Eligible for abiraterone therapy. Review Status Under Review Pre Noc Submission No NOC Date February 15, 2018 Manufacturer Janssen Inc. Sponsor BC

2019 CADTH - Pan Canadian Oncology Drug Review

132. Lynparza for Newly Diagnosed Ovarian Cancer – Details

Lynparza for Newly Diagnosed Ovarian Cancer – Details Lynparza for Newly Diagnosed Ovarian Cancer – Details | CADTH.ca Find the information you need Lynparza for Newly Diagnosed Ovarian Cancer – Details Lynparza for Newly Diagnosed Ovarian Cancer – Details Project Number pCODR 10174 Brand Name Lynparza Generic Name Olaparib Strength 100 mg and 150 mg Tumour Type Gynecology Indication Ovarian Cancer Funding Request As monotherapy for the maintenance treatment of adult patients with newly (...) diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy, until disease progression or up to 2 years if no evidence of disease. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated. Review Status Open for Feedback on Recommendation Pre Noc Submission Yes NOC Date May 6

2019 CADTH - Pan Canadian Oncology Drug Review

133. Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details

Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Project Number pCODR 10149 Brand Name Xtandi Generic Name Enzalutamide Strength 40 mg Tumour Type Genitourinary Indication Non-metastatic castration-resistant (...) prostate cancer Funding Request High risk, non-metastatic castration-resistant prostate cancer Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date December 20, 2018 Manufacturer Astellas Pharma Canada, Inc. Sponsor Astellas Pharma Canada, Inc. Submission Date September 24, 2018 Submission Deemed Complete October 9, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ October 9, 2018 Check-point meeting November 20, 2018 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

134. Zytiga for Prostate Cancer – Details

Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details | CADTH.ca Find the information you need Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details Project Number pCODR 10166 Brand Name Zytiga Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed with metastatic prostate cancer without small-cell histologic features (may have received prior surgery or radiation therapy (...) for local disease or palliative therapy); Less than 3 months of androgen deprivation therapy for metastatic disease (may have received prior adjuvant/neoadjuvant hormone therapy); Eligible for abiraterone therapy Review Status Withdrawn Clarification BC Cancer Agency has requested a voluntary withdrawal of the pCODR 10166 Abiraterone (Zytiga) for PC Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue

2019 CADTH - Pan Canadian Oncology Drug Review

135. Imfinzi for Non-Small Cell Lung Cancer – Details

Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details Project Number pCODR 10131 Brand Name Imfinzi Generic Name Durvalumab Strength 50 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC

2019 CADTH - Pan Canadian Oncology Drug Review

136. Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details

Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10150 Brand Name Ibrance (with Faslodex) Generic Name Palbociclib (with Fulvestrant) Strength 75 mg, 100 mg & 125 mg Tumour Type Breast (...) Indication Advanced or Metastatic Breast Cancer Funding Request In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy, Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist Review Status Notification to Implement Issued Pre Noc Submission No NOC Date May

2019 CADTH - Pan Canadian Oncology Drug Review

137. Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details

Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Project Number pCODR 10169 (...) Brand Name Ogivri Generic Name Trastuzumab Strength 150 mg/vial and 440 mg/vial Tumour Type Breast / Gastrointestinal Indication Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar Funding Request For the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel

2019 CADTH - Pan Canadian Oncology Drug Review

138. Trastuzumab for Breast and Gastric Cancer Biosimilar – Details

Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Project Number pCODR 10160 Brand Name TBD Generic Name Trastuzumab Strength Tumour Type Breast & Gastrointestinal Indication Breast and Gastric Cancer Biosimilar Funding Request Breast and Gastric Cancer

2019 CADTH - Pan Canadian Oncology Drug Review

139. Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Project Number pCODR 10151 Brand Name Xalkori Generic Name Crizotinib Strength 200 mg & 250 mg Tumour Type Lung Indication ROS1-positive advanced Non-Small Cell Lung (...) Cancer Funding Request As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 28, 2017 Manufacturer Pfizer Canada Inc. Sponsor Cancer Care Ontario Lung Cancer Drug Advisory Committee Submission Date October 30, 2018 Submission Deemed Complete November 13, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ November 13

2019 CADTH - Pan Canadian Oncology Drug Review

140. Vizimpro for Non-Small Cell Lung Cancer – Details

Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details Project Number pCODR 10129 Brand Name Vizimpro Generic Name Dacomitinib Strength 15 mg, 30 mg & 45 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the first-line treatment of patients with locally advanced or metastatic non (...) ‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date February 26, 2019 Manufacturer Pfizer Canada Inc. Sponsor Pfizer Canada Inc. Submission Date September 19, 2018 Submission Deemed Complete October 3, 2018 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ October 3, 2018 Check-point meeting December 4, 2018 pERC Meeting March 21, 2019 Initial

2019 CADTH - Pan Canadian Oncology Drug Review